Head-to-head · WeighScore
Wellorithm vs Zealthy
The verdict
Wellorithm takes it — 48.5/100 to 46.7/100, but only just.
Wellorithm grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Four compounded routes plus four branded pens — and not one price anywhere on the public site. Zealthy is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Wellorithm | Zealthy |
|---|---|---|
| WeighScore | 48.5/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #486 | #496 |
| Semaglutide | Pricing not published | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | Pricing not published | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | 49 states (not Louisiana) | 34 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #486 · C
Strengths
- Both molecules in BOTH routes — compounded semaglutide and tirzepatide as injections and as oral dissolving tablets
- Four branded pens on the same account: Mounjaro, Ozempic, Wegovy and Zepbound
- Sermorelin offered alongside the GLP-1 line
- 24/7 phone support on a published number
Where it loses points
- No price appears anywhere on the public site — /pricing 404s and every product CTA leads to a 2-minute intake quiz, so no cost can be compared before signing up
- The site contradicts itself on coverage: the homepage says "Serving All 50 States" while its own FAQ says 49 states and excludes Louisiana
- The four clinicians presented as "board-certified obesity specialists" are listed as Cardiac Surgery, Pediatric Clinic, Gynecology and Cardiac Surgery — none in obesity medicine
- "100% Customer Satisfaction" is stated as a headline fact and is not a substantiable claim
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.